OKYOHealthcare · BiotechnologyOKYO Stock Forecast: OKYO Pharma Ltd. Price Predictions for 2026-2027
The 3 Wall Street analysts covering OKYO Pharma Ltd. hold a median 12-month price target of $7 — +369.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 26 of 100 as at 27 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
OKYO stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores OKYO Pharma Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (76): Smaller than most of the companies we track.
Growth (8): Sales and profits are flat, shrinking, or growing more slowly than they were.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
OKYO stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on OKYO, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +369.8% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 13 July 2026 | HC Wainwright & Co. | Maintains | Buy | $7.00 → $5.00 |
| 20 Feb 2026 | Piper Sandler | Initiates | Overweight | — |
| 8 Dec 2025 | B. Riley Securities | Initiates | Buy | — |
| 23 Sept 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 5 May 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 5 May 2025 | HC Wainwright& Co. | Reiterates | Buy | — |
| 18 Feb 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 14 Feb 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 10 Feb 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 24 Oct 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 16 Oct 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 27 Aug 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 12 July 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 11 July 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 22 Mar 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 8 Jan 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 5 Dec 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 2 Nov 2023 | HC Wainwright & Co. | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
This page is one stock. Monday covers all of them.
OKYO appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.
OKYO vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 27 Oct 2026, OKYO Pharma Ltd. returned −43.8% against +13.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
OKYO analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
OKYO Pharma Ltd. (OKYO) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −6.0×
- Price / sales
- —
- Price / book
- 6.3×
- EV / EBITDA
- −6.5×
Cheaper than 91% of US stocks
Cheaper than 15% of US stocks
Cheaper than 83% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- 0.0%
- Net margin
- 0.0%
Higher than 32% of US stocks
Higher than 30% of US stocks
- Return on equity
- −263.8%
- Return on assets
- −43.1%
- Dividend yield
- 0.0%
Higher than 6% of US stocks
Higher than 9% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
OKYO Pharma Ltd. (OKYO) statistics: revenue, profit & scale
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
OKYO Pharma Ltd. has a market value of $75.6M and an enterprise value of $55.0M.
Trailing P/E: −6.0×; forward P/E: −2.2× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
OKYO Pharma Ltd. employs 5 people.
Data provided by Twelve Data
OKYO vs competitors
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own OKYO Pharma Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Frequently asked questions about OKYO stock
What is the OKYO stock price forecast for 2026-2027?
The 3 Wall Street analysts covering OKYO Pharma Ltd. have a median 12-month price target of $7, with estimates ranging from $5 to $13. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is OKYO stock a buy right now?
Of the 3 analysts covering OKYO Pharma Ltd., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks OKYO Pharma Ltd. 26 out of 100 across roughly 4,600 US stocks as at 27 Oct 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank OKYO?
As at 27 Oct 2026, OKYO Pharma Ltd. ranks 26 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (76 of 100).
Will OKYO stock go up?
No one can know that. What the data says: the median 12-month target from 3 analysts implies +369.8% from the last close, and Ticker Nerd's factor model ranks OKYO Pharma Ltd. 26 out of 100 as at 27 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the OKYO stock forecast for 2030?
No analyst covering OKYO Pharma Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for OKYO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $13 over the next 12 months.
How has OKYO stock performed over the past year?
OKYO Pharma Ltd. returned -43.8% over the 12 months to 27 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
What does OKYO Pharma Ltd. do?
OKYO Pharma Ltd. is a clinical-stage biopharmaceutical company focused on developing therapies for neuropathic corneal pain and inflammatory eye diseases.
About OKYO Pharma Ltd.
OKYO Pharma Ltd. is a clinical-stage biopharmaceutical company focused on developing therapies for neuropathic corneal pain and inflammatory eye diseases. The company concentrates on ophthalmology and corneal health, with research programs aimed at conditions such as dry eye disease, allergic conjunctivitis, uveitis, and ocular pain. Its pipeline includes urcosimod, an investigational candidate being studied for multiple eye-related indications, and OK-201, another development-stage therapy for ocular pain. OKYO Pharma Ltd. operates as a research and development business in the healthcare sector, targeting unmet needs in diseases affecting the cornea and anterior segment of the eye. Based in London and incorporated in Guernsey, the company plays a specialized role in the biopharmaceutical market by advancing non-opioid and non-steroidal treatment approaches for complex eye disorders.
CEO Mr. Robert J. Dempsey M.B.A. · 5 employees · United Kingdom · https://okyopharma.com